ReviewFrontiers in immunology2026
Neoantigen-based cancer vaccines: a mechanistic and clinical review of personalised melanoma immunotherapy.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Personalized mRNA Neoantigen Vaccines in Cancer: Linking Precision Antigen Selection, Immune Remodeling, and Checkpoint Blockade.International journal of molecular sciences · 2026Review
- Advances in Therapeutic Melanoma Vaccines (2010-2025).Vaccines · 2026Review
- Advances in improving cancer immunotherapy with nanotechnology: from smart nanoparticles to synergistic combination strategies.Molecular cancer · 2026Review
- Interleukin-1β Gene (Current oncology (Toronto, Ont.) · 2026Article
- Interleukin-1β Gene (Genes · 2026Observational
- Review
- Therapeutic melanoma vaccines: Platforms, neoantigen strategies, and emerging combination immunotherapies.Therapeutic advances in vaccines and immunotherapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanoma, owing to its high tumour mutational burden (TMB) and inherent immunogenicity, has emerged as a prime target for neoantigen-based customised cancer vaccines. Such vaccines may synergise with immune checkpoint inhibitors (ICIs) by harnessing patient-specific mutations to trigger targeted T-cell responses. This review systematically summarises and evaluates the clinical evidence and molecular mechanisms underlying customised neoantigen vaccines in melanoma, based on key clinical trial data. A central finding is that vaccine platform choice strongly influences, rather than rigidly determines, the dominant immunological pathway. Messenger RNA (mRNA) platforms generally favour endogenous antigen expression and MHC class I presentation, often eliciting robust CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.